Vaginal Microbiome Genomics Analysis 2025: Unleashing Precision Diagnostics & Market Growth

Vaginal Microbiome Genomics Analysis 2025: Unleashing Precision Diagnostics & Market Growth

May 24, 2025
by

Vaginal Microbiome Genomics Analysis in 2025: Transforming Women’s Health with Next-Gen Sequencing and Predictive Insights. Explore the Market Forces, Breakthrough Technologies, and Future Opportunities Shaping This Rapidly Evolving Sector.

The vaginal microbiome genomics analysis sector is experiencing rapid evolution in 2025, driven by advances in next-generation sequencing (NGS), bioinformatics, and a growing recognition of the microbiome’s role in women’s health. The market is shaped by increasing demand for precision diagnostics, personalized therapeutics, and preventative care, with a focus on conditions such as bacterial vaginosis, recurrent urinary tract infections, and preterm birth. Key trends and drivers are outlined below.

  • Technological Advancements: The adoption of high-throughput NGS platforms and improved metagenomic analysis pipelines is enabling more comprehensive and accurate profiling of the vaginal microbiome. Companies such as Illumina and Thermo Fisher Scientific are at the forefront, providing sequencing instruments and reagents tailored for microbiome research. Enhanced bioinformatics tools are facilitating the interpretation of complex microbial communities, supporting both research and clinical applications.
  • Clinical Integration and Diagnostics: There is a marked shift toward integrating vaginal microbiome genomics into routine gynecological care. Diagnostic companies, including Baylor College of Medicine (through its Human Genome Sequencing Center) and FemTech DK, are developing and commercializing assays for rapid, point-of-care detection of dysbiosis and pathogen identification. These diagnostics are increasingly used to guide personalized treatment strategies, particularly in fertility clinics and obstetrics.
  • Personalized Therapeutics and Probiotics: The rise of precision medicine is fueling the development of microbiome-based therapeutics. Companies such as Evvy and MicroGen Biotech are leveraging genomic insights to design targeted probiotic formulations and interventions aimed at restoring healthy vaginal flora. Clinical trials and pilot programs are underway to validate efficacy and safety, with regulatory pathways becoming clearer.
  • Data Integration and AI: The sector is witnessing increased use of artificial intelligence and machine learning to analyze large-scale microbiome datasets. This is enabling the identification of novel biomarkers and predictive models for disease risk and treatment response. Companies like Illumina and Thermo Fisher Scientific are investing in cloud-based platforms and data-sharing initiatives to accelerate discovery and clinical translation.
  • Regulatory and Ethical Considerations: As clinical applications expand, regulatory agencies are establishing clearer guidelines for microbiome-based diagnostics and therapeutics. Industry bodies and consortia are collaborating to address data privacy, standardization, and equitable access, ensuring responsible innovation.

Looking ahead, the vaginal microbiome genomics analysis market is poised for continued growth, with increasing adoption in clinical practice, expanding research collaborations, and ongoing innovation in sequencing and data analytics. The convergence of genomics, digital health, and personalized medicine is expected to drive new product launches and partnerships through 2025 and beyond.

Market Size, Growth Rate, and Forecasts Through 2030

The global market for vaginal microbiome genomics analysis is experiencing robust growth, driven by increasing awareness of women’s health, advances in next-generation sequencing (NGS) technologies, and a surge in research on the role of the vaginal microbiome in gynecological and reproductive health. As of 2025, the market is characterized by a growing number of commercial and academic initiatives focused on leveraging genomics to better understand, diagnose, and treat conditions such as bacterial vaginosis, recurrent urinary tract infections, and preterm birth.

Key industry players are expanding their offerings in microbiome sequencing and analysis. Illumina, Inc., a global leader in NGS platforms, continues to provide sequencing technologies widely adopted in microbiome research, including targeted 16S rRNA gene sequencing and whole metagenome shotgun approaches. Thermo Fisher Scientific also supports the market with its Ion Torrent sequencing systems and reagents tailored for microbial genomics. These companies are investing in workflow automation and bioinformatics solutions to streamline sample-to-answer processes, making vaginal microbiome analysis more accessible to clinical and research laboratories.

Emerging companies are focusing on direct-to-consumer and clinical testing. Eubiome and Juno Bio offer specialized vaginal microbiome testing services, providing both consumers and healthcare providers with actionable insights into microbial composition and potential health implications. These services typically utilize high-throughput sequencing and proprietary bioinformatics pipelines to deliver personalized reports.

The market is projected to grow at a compound annual growth rate (CAGR) exceeding 15% through 2030, with North America and Europe leading in adoption due to strong research infrastructure and supportive regulatory environments. Asia-Pacific is expected to see accelerated growth, driven by rising healthcare investments and increasing participation in women’s health research.

Looking ahead, the vaginal microbiome genomics analysis market is poised for further expansion as clinical guidelines begin to incorporate microbiome-based diagnostics and therapeutics. Ongoing collaborations between sequencing technology providers, academic institutions, and pharmaceutical companies are expected to yield new biomarkers and targeted interventions. The integration of artificial intelligence and machine learning into bioinformatics pipelines will further enhance the interpretation of complex microbiome data, supporting the development of precision medicine approaches in gynecology.

Technological Innovations: Sequencing Platforms and Bioinformatics

The field of vaginal microbiome genomics analysis is experiencing rapid technological innovation, particularly in sequencing platforms and bioinformatics, as we move through 2025. High-throughput sequencing technologies have become the cornerstone of microbiome research, enabling comprehensive profiling of microbial communities at unprecedented resolution. Leading the market, Illumina continues to dominate with its short-read sequencing platforms, such as the NovaSeq and NextSeq series, which are widely adopted for 16S rRNA gene amplicon sequencing and metagenomic shotgun approaches. These platforms offer high accuracy and throughput, making them suitable for large-scale cohort studies and clinical research into the vaginal microbiome.

Long-read sequencing technologies are also gaining traction, with Pacific Biosciences (PacBio) and Oxford Nanopore Technologies providing solutions that enable full-length 16S rRNA gene sequencing and even complete genome assemblies of key vaginal microbes. These advances are crucial for resolving strain-level diversity and detecting low-abundance or novel taxa, which are often missed by short-read methods. The ability to generate contiguous assemblies is particularly valuable for characterizing the functional potential of the vaginal microbiome and its role in health and disease.

On the bioinformatics front, there is a strong push towards standardized, scalable, and clinically validated pipelines. Open-source tools such as QIIME 2 and mothur remain foundational, but commercial solutions are emerging to address the needs of clinical laboratories and translational research. Companies like Illumina and QIAGEN are integrating bioinformatics suites with their sequencing platforms, offering end-to-end workflows that include quality control, taxonomic classification, and functional annotation. These platforms are increasingly leveraging cloud computing and artificial intelligence to handle large datasets and extract clinically relevant insights.

Another notable trend is the development of curated reference databases specific to the vaginal microbiome, which improve the accuracy of taxonomic assignments and functional predictions. Industry collaborations and consortia are working to expand these resources, facilitating cross-study comparisons and meta-analyses. Furthermore, regulatory considerations are shaping the landscape, with companies seeking compliance with standards for clinical diagnostics, such as those set by the FDA and international bodies.

Looking ahead, the next few years are expected to bring further integration of multi-omics data (genomics, transcriptomics, metabolomics) and real-time sequencing capabilities, enabling more precise and personalized approaches to women’s health. As sequencing costs continue to decline and bioinformatics tools become more user-friendly, vaginal microbiome genomics analysis is poised to transition from research settings into routine clinical practice, supporting diagnostics, prognostics, and therapeutic development.

Leading Companies and Strategic Partnerships

The vaginal microbiome genomics analysis sector is experiencing rapid growth in 2025, driven by advances in sequencing technologies, increased awareness of women’s health, and a surge in strategic collaborations. Several pioneering companies are shaping the landscape, leveraging genomics to develop diagnostics, therapeutics, and personalized health solutions.

One of the most prominent players is Illumina, whose next-generation sequencing (NGS) platforms are foundational for high-throughput microbiome analysis. Illumina’s technology is widely adopted by clinical laboratories and research institutions for metagenomic profiling, enabling detailed characterization of the vaginal microbiota. The company continues to expand its partnerships with women’s health startups and academic consortia to facilitate large-scale studies and clinical applications.

Another key innovator is Thermo Fisher Scientific, offering a comprehensive suite of reagents, instruments, and bioinformatics tools tailored for microbiome research. Thermo Fisher’s Ion Torrent sequencing systems and proprietary analysis pipelines are frequently used in clinical trials and translational research focused on vaginal health, supporting both discovery and validation of microbial biomarkers.

In the direct-to-consumer and clinical diagnostics space, Microba and uBiome (noting that uBiome’s operations have been subject to significant changes in recent years) have contributed to the development of accessible vaginal microbiome testing kits. These companies have established partnerships with healthcare providers and research organizations to integrate microbiome insights into routine gynecological care and fertility assessments.

Strategic partnerships are a hallmark of the sector’s evolution. For example, Illumina has entered collaborations with women’s health biotech firms to co-develop diagnostic assays and expand the clinical utility of microbiome data. Similarly, Thermo Fisher Scientific has partnered with academic medical centers to validate new sequencing-based tests for bacterial vaginosis and other vaginal dysbioses.

Emerging companies such as Joylux are also entering the field, focusing on integrating genomics with digital health platforms to deliver personalized recommendations for vaginal health. These collaborations are expected to accelerate the translation of microbiome research into actionable clinical solutions over the next few years.

Looking ahead, the sector is poised for further consolidation and innovation, with leading genomics companies deepening their engagement with women’s health specialists, fertility clinics, and pharmaceutical developers. The ongoing formation of multi-stakeholder consortia and public-private partnerships is anticipated to drive standardization, regulatory approval, and broader adoption of vaginal microbiome genomics analysis in clinical practice.

Clinical Applications: Diagnostics, Therapeutics, and Personalized Medicine

The clinical applications of vaginal microbiome genomics analysis are rapidly expanding in 2025, driven by advances in sequencing technologies, bioinformatics, and a growing understanding of the microbiome’s role in women’s health. Genomic profiling of the vaginal microbiome is increasingly being integrated into diagnostics, therapeutics, and personalized medicine, with several companies and research institutions at the forefront.

In diagnostics, next-generation sequencing (NGS) platforms are enabling high-resolution identification of microbial communities associated with conditions such as bacterial vaginosis (BV), vulvovaginal candidiasis, and sexually transmitted infections. Companies like Illumina and Thermo Fisher Scientific provide sequencing instruments and reagents widely used in clinical and research laboratories for microbiome analysis. These tools allow clinicians to move beyond traditional culture-based diagnostics, offering more comprehensive and rapid detection of dysbiosis and pathogen presence.

On the therapeutic front, the identification of specific microbial signatures linked to disease states is informing the development of targeted interventions. For example, live biotherapeutic products (LBPs) and vaginal probiotics are being designed to restore healthy Lactobacillus-dominated microbiota. Companies such as Rebiotix (a Ferring company) and Seres Therapeutics are leveraging microbiome genomics to develop and test such therapeutics, with clinical trials underway for recurrent BV and other indications. Additionally, personalized approaches are emerging, where interventions are tailored based on an individual’s unique microbiome profile, aiming to improve efficacy and reduce recurrence rates.

Personalized medicine is a particularly promising area, as large-scale genomic datasets and machine learning models enable risk stratification and individualized care plans. Companies like uBiome (historically a pioneer, though no longer active) and emerging startups are working on direct-to-consumer and clinician-facing platforms that provide actionable insights from vaginal microbiome sequencing. These platforms can inform decisions on antibiotic stewardship, contraceptive choices, and fertility treatments, reflecting a shift toward precision gynecology.

Looking ahead, the next few years are expected to see further integration of vaginal microbiome genomics into routine clinical workflows, supported by regulatory advances and growing evidence bases. Collaborations between sequencing technology providers, biopharmaceutical companies, and healthcare systems are likely to accelerate the translation of research findings into standardized care. As the field matures, the focus will increasingly be on longitudinal monitoring, multi-omics integration, and the development of robust clinical guidelines for microbiome-informed interventions.

Regulatory Landscape and Quality Standards

The regulatory landscape for vaginal microbiome genomics analysis is rapidly evolving as the field matures and clinical applications expand. In 2025, regulatory agencies are increasingly focused on ensuring the accuracy, reproducibility, and safety of microbiome-based diagnostics and therapeutics, particularly those targeting women’s health. The U.S. Food and Drug Administration (FDA) continues to play a central role, with ongoing efforts to clarify the regulatory pathways for next-generation sequencing (NGS)-based microbiome tests. The FDA’s Center for Devices and Radiological Health (CDRH) has issued guidance on the validation of NGS-based in vitro diagnostic (IVD) devices, emphasizing analytical validity, clinical validity, and transparency in bioinformatics pipelines. This guidance is particularly relevant for companies developing vaginal microbiome analysis kits and platforms, as it sets expectations for performance metrics and data integrity (U.S. Food and Drug Administration).

In Europe, the In Vitro Diagnostic Regulation (IVDR), which became fully applicable in 2022, is now being stringently enforced for microbiome genomics products. The IVDR requires comprehensive clinical evidence, robust quality management systems, and post-market surveillance for all IVDs, including those analyzing the vaginal microbiome. Companies must demonstrate conformity with harmonized standards such as ISO 15189 (medical laboratories) and ISO 13485 (medical device quality management), which are increasingly prerequisites for market access (International Organization for Standardization). The European Medicines Agency (EMA) and national competent authorities are also monitoring the development of live biotherapeutic products (LBPs) and microbiome-based interventions, with a focus on safety and efficacy.

Industry leaders such as Illumina and Thermo Fisher Scientific are actively collaborating with regulatory bodies to standardize sequencing workflows and data interpretation for clinical microbiome applications. These companies provide validated NGS platforms and reagents that comply with regulatory requirements, supporting laboratories in achieving accreditation and ensuring consistent results. Additionally, organizations like Microbiome Standards are working to harmonize protocols and reference materials, addressing challenges related to sample collection, DNA extraction, and bioinformatics analysis.

Looking ahead, the next few years are expected to bring further harmonization of global standards, with increased emphasis on data privacy, interoperability, and patient consent, especially as vaginal microbiome genomics becomes integrated into routine gynecological care and personalized medicine. Regulatory agencies are anticipated to issue more specific guidance on clinical trial design, endpoints, and real-world evidence for microbiome-based diagnostics and therapeutics. As the field advances, ongoing collaboration between industry, regulators, and standards organizations will be critical to ensuring the quality, safety, and clinical utility of vaginal microbiome genomics analysis.

Data Privacy, Ethics, and Patient Engagement

The rapid expansion of vaginal microbiome genomics analysis in 2025 is accompanied by heightened attention to data privacy, ethical considerations, and patient engagement. As sequencing technologies become more accessible and clinical applications broaden, the collection and handling of sensitive genomic and health data require robust frameworks to ensure patient trust and regulatory compliance.

Data privacy is a central concern, given the intimate nature of vaginal microbiome data and its potential to reveal not only health status but also aspects of identity and reproductive history. Companies specializing in microbiome genomics, such as Illumina and Thermo Fisher Scientific, have implemented advanced encryption and de-identification protocols to safeguard patient information. These measures are designed to comply with evolving regulations, including the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States. In 2025, there is a trend toward harmonizing global standards, with industry groups and regulatory bodies working to establish best practices for cross-border data sharing and secondary use of genomic data.

Ethical considerations extend beyond privacy to include informed consent, data ownership, and the potential for discrimination. Leading organizations, such as the International Human Microbiome Consortium, are actively developing guidelines to ensure that participants are fully informed about how their data will be used, stored, and potentially shared for research or commercial purposes. There is also a growing emphasis on ensuring that research and clinical applications are inclusive, addressing the historical underrepresentation of diverse populations in genomics studies. This is particularly relevant in vaginal microbiome research, where population-specific differences can have significant implications for women’s health.

Patient engagement is increasingly recognized as essential for both ethical and scientific reasons. Companies like Illumina and Thermo Fisher Scientific are investing in user-friendly reporting tools and educational resources to help patients understand their results and the broader implications of microbiome analysis. Digital platforms are being developed to facilitate ongoing communication between patients, clinicians, and researchers, fostering a collaborative approach to health management and research participation.

Looking ahead, the next few years are expected to see further integration of patient-centric models, with dynamic consent mechanisms and real-time data access controls. These advances aim to empower individuals, enhance transparency, and build public trust, which are critical for the continued growth and societal acceptance of vaginal microbiome genomics analysis.

Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets

The global landscape for vaginal microbiome genomics analysis is rapidly evolving, with significant regional differences in research activity, clinical adoption, and commercial development. As of 2025, North America, Europe, and Asia-Pacific are the primary hubs for innovation, while emerging markets are beginning to establish foundational capabilities.

North America remains at the forefront, driven by robust investment in genomics, a mature biotechnology sector, and a strong focus on women’s health. The United States, in particular, hosts leading companies such as Illumina, which provides next-generation sequencing (NGS) platforms widely used in microbiome research, and Thermo Fisher Scientific, offering comprehensive genomics solutions. Clinical adoption is accelerating, with academic medical centers and specialized women’s health clinics integrating microbiome profiling into diagnostics and personalized care. Regulatory clarity from agencies like the FDA is fostering confidence in clinical applications, and public-private partnerships are supporting translational research.

Europe is characterized by strong academic consortia and cross-border collaborations, particularly in countries such as the UK, Germany, and the Netherlands. The region benefits from coordinated funding through the European Union and a focus on harmonizing standards for microbiome data. Companies like QIAGEN (Germany/Netherlands) are prominent, supplying sample preparation and bioinformatics tools tailored for microbiome genomics. European research initiatives are increasingly addressing the role of the vaginal microbiome in reproductive health, fertility, and infection risk, with several clinical trials underway. Regulatory frameworks such as the In Vitro Diagnostic Regulation (IVDR) are shaping the pathway for clinical-grade microbiome tests.

Asia-Pacific is witnessing rapid growth, led by China, Japan, and South Korea. Investment in genomics infrastructure is expanding, with companies like BGI Genomics (China) scaling up sequencing capacity and offering microbiome analysis services. Regional governments are supporting precision medicine initiatives, and there is growing interest in the application of vaginal microbiome genomics for maternal health and infectious disease management. However, clinical adoption is still in early stages compared to North America and Europe, with regulatory and reimbursement pathways under development.

Emerging markets in Latin America, the Middle East, and Africa are beginning to engage with vaginal microbiome genomics, primarily through academic collaborations and pilot projects. Access to advanced sequencing technologies is limited, but international partnerships and technology transfer initiatives are expected to accelerate capacity building over the next few years. The focus in these regions is on establishing baseline microbiome data and exploring links to prevalent women’s health challenges.

Looking ahead, regional disparities in access, regulatory harmonization, and clinical integration are likely to persist, but ongoing investment and collaboration are expected to drive broader adoption of vaginal microbiome genomics analysis worldwide.

The investment landscape for vaginal microbiome genomics analysis has evolved rapidly, reflecting the growing recognition of the microbiome’s role in women’s health and the commercial potential of precision diagnostics and therapeutics. In 2025, the sector is characterized by a mix of established genomics companies, emerging startups, and strategic partnerships with pharmaceutical and diagnostics firms. Funding activity is robust, with venture capital, corporate investment, and public grants fueling innovation and expansion.

Key players in the vaginal microbiome genomics space include Illumina, a global leader in sequencing technology, which provides the foundational platforms for high-throughput microbiome analysis. Thermo Fisher Scientific is another major supplier of sequencing and sample preparation solutions, supporting both research and clinical applications. These companies have continued to invest in expanding their genomics capabilities, with a focus on user-friendly workflows and clinical-grade data quality, which are critical for translational microbiome research.

On the startup front, companies such as Juno Bio have attracted significant venture funding to develop direct-to-consumer and clinical testing services focused on the vaginal microbiome. Juno Bio, for example, has raised capital to scale its sequencing-based diagnostics and to build large, proprietary datasets that can be leveraged for biomarker discovery and personalized health insights. Similarly, SNIPR Biome is developing CRISPR-based therapeutics targeting pathogenic bacteria in the vaginal environment, with funding rounds supported by both venture capital and strategic investors.

Pharmaceutical and diagnostics companies are increasingly entering the field through partnerships and acquisitions. For instance, bioMérieux, a leader in in vitro diagnostics, has shown interest in expanding its women’s health portfolio by collaborating with microbiome-focused startups and academic groups. These collaborations often involve co-development agreements, joint research initiatives, and licensing deals, reflecting a trend toward integrated solutions that combine genomics, bioinformatics, and clinical validation.

Public funding agencies, particularly in North America and Europe, continue to support vaginal microbiome research through grants and innovation programs, recognizing its potential to address unmet needs in reproductive health, infection prevention, and personalized medicine. The outlook for 2025 and beyond suggests sustained investment, with increased attention to regulatory pathways, reimbursement models, and the translation of microbiome discoveries into clinically actionable products.

  • Sequencing technology providers like Illumina and Thermo Fisher Scientific remain foundational to the sector.
  • Startups such as Juno Bio and SNIPR Biome are driving innovation and attracting venture capital.
  • Strategic partnerships with established diagnostics firms like bioMérieux are accelerating commercialization.
  • Public and private funding is expected to remain strong, supporting both research and market entry of new products.

Future Outlook: Opportunities, Challenges, and Disruptive Potential

The future of vaginal microbiome genomics analysis is poised for significant transformation as advances in sequencing technologies, bioinformatics, and clinical integration converge. By 2025, the field is expected to move beyond basic taxonomic profiling toward comprehensive functional genomics, enabling a deeper understanding of the interplay between microbial communities and women’s health. This evolution is driven by the increasing accessibility of next-generation sequencing (NGS) platforms and the development of robust analytical pipelines tailored for the unique challenges of low-biomass, high-variability vaginal samples.

Key industry players are accelerating this progress. Illumina continues to dominate the sequencing market, providing platforms and reagents that underpin most current vaginal microbiome studies. Their ongoing innovation in short-read and emerging long-read technologies is expected to further reduce costs and improve resolution, making large-scale, longitudinal studies more feasible. Meanwhile, Thermo Fisher Scientific is expanding its portfolio of sample preparation and sequencing solutions, with a focus on clinical-grade reproducibility and regulatory compliance—critical for translating research findings into diagnostics and therapeutics.

On the bioinformatics front, companies like QIAGEN are investing in cloud-based analysis platforms and curated reference databases, addressing the need for standardized, reproducible pipelines that can handle the complexity of vaginal microbiome data. These tools are expected to facilitate the identification of novel biomarkers for conditions such as bacterial vaginosis, preterm birth risk, and susceptibility to sexually transmitted infections.

The integration of multi-omics—combining genomics, transcriptomics, and metabolomics—represents a disruptive opportunity. Companies such as Illumina and Thermo Fisher Scientific are actively developing platforms that support multi-omic workflows, which could enable a systems-level understanding of host-microbe interactions and pave the way for personalized interventions.

However, challenges remain. Standardization of sampling, data analysis, and interpretation is still lacking, impeding cross-study comparisons and clinical translation. Privacy and ethical considerations around genomic data, especially in sensitive health domains, will require robust frameworks and transparent communication with participants. Additionally, the field must address the underrepresentation of diverse populations in current datasets, which limits the generalizability of findings.

Looking ahead, the next few years are likely to see the emergence of validated, clinically actionable microbiome-based diagnostics and therapeutics, supported by partnerships between sequencing technology providers, bioinformatics companies, and women’s health organizations. As regulatory pathways clarify and evidence accumulates, vaginal microbiome genomics analysis could become a cornerstone of precision gynecology, offering new avenues for disease prevention, early detection, and individualized care.

Sources & References

Vaginal Microbiome

Kara Squires

Kara Squires is a distinguished writer and thought leader in the realms of new technologies and financial technology (fintech). She holds a Bachelor’s degree in Information Systems from the prestigious Queen's School of Business at Queen’s University, where she honed her understanding of emerging technologies and their implications for the financial sector. With over a decade of experience, Kara has contributed her insights to notable publications and platforms, shaping conversations around digital transformation and innovation. Previously, she served as a senior analyst at ThinkBank, where she guided strategic initiatives to integrate cutting-edge technology within traditional banking frameworks. Her expertise bridges the gap between technology and finance, making her a sought-after voice in the industry.

Leave a Reply

Your email address will not be published.

Don't Miss

Stuck Without Power? Discover How EV Owners are Beating Charging Obstacles

Stuck Without Power? Discover How EV Owners are Beating Charging Obstacles

Charging Woes for Electric Car Drivers Electric vehicle (EV) owners
The Future of Driving: Toyota RAV4 Goes Autonomous

The Future of Driving: Toyota RAV4 Goes Autonomous

The Toyota RAV4 is poised to integrate autonomous driving technology.